Inclusion Criteria:  Signed informed consent Burn of thermal origin Patients presenting with partial thickness burns covering < 5% TBSA for study treatment TBSA covered with any burn type is ≤15%, with a maximum of 10% being full thickness burns Clean wounds with ≤10% necrotic tissue Patients presenting with moderate to high exuding wounds Serous or Serosanguinous exudate Patient is not contraindicated for the dressing to which he/she is assigned  Exclusion Criteria:  Electrical Burns Chemical Burns including acidic or basic sources Ionizing radiation injuries Dry wounds Neonates Patients with delayed presentation for burn care (>72 hours from time of injury) Before entry into the study, treatment to the study wound included an active agent that would confound study results, as determined by the Investigator Burns under study treatment transitioning to full thickness, or deep partial thickness burns requiring surgical treatment Clinically infected burn Patients with insulin dependent diabetes mellitus Patients treated with systemic glucocorticosteroids, except patients taking occasional doses or doses less than 10mg prednisolone per day or equivalent Patients who have used immunosuppressive agents, radiation or chemotherapy within past 30 days Known allergy/hypersensitivity to any of the components of the investigation products History of comorbid conditions or diagnoses associated with higher risk of infection as determined by the Investigator Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer, severe anemia) Patients that are not expected to comply with the investigation due to physical and/or mental conditions Pregnancy Participation in other clinical investigation(s) within 1 month prior to start of the investigation Previously enrolled in this investigation